Joshua Reuss is an Oncology physician affiliated with Georgetown University. OpenAlex indexes 138 publications with 2,288 citations (h-index 21); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3800 Reservoir Road NW Lccc, Podium B
Washington, DC 200072113
Telephone
202-444-2223Provider last certified this registry record 17 Jun 2020.
Clinical trials
- Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Sponsor: Georgetown University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202510 payments$10,537openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20254 payments
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.5%Kinase inhibitor49.5%Tagrisso73%Retevmo14%Erlotinib Hcl13%Part D<11 patientsNervous system
23.7%Opioid Agonist16.1%Oxycodone Hcl100%Part D≥11 patientsOther antidepressants7.5%Mirtazapine100%Part D<11 patientsMetabolism & gastrointestinal
18.8%Corticosteroid10.2%Prednisone100%Part D≥11 patientsSerotonin-3 Receptor Antagonist8.6%Ondansetron Hcl100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1
Journal of Clinical Oncology
2025 - Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Journal of Clinical Oncology
2025 - Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis
JCO Oncology Practice
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Augusto Pichard, MD
Georgetown University
Virginia Steen
Georgetown University
Joseph Verbalis
Georgetown University
Craig Kessler
Georgetown University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”